TerminatedPHASE1, PHASE2NCT03878199

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Studying Acute panmyelosis with myelofibrosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ohio State University Comprehensive Cancer Center
Principal Investigator
Uma Borate, MD
The Ohio State Comprehensive Cancer Center
Intervention
Allogeneic Hematopoietic Stem Cell Transplantation(procedure)
Enrollment
12 enrolled
Eligibility
18 years · All sexes
Timeline
20192025

Study locations (3)

Collaborators

Incyte Corporation · Jazz Pharmaceuticals

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03878199 on ClinicalTrials.gov

Other trials for Acute panmyelosis with myelofibrosis

Additional recruiting or active studies for the same condition.

See all trials for Acute panmyelosis with myelofibrosis

← Back to all trials